HOPKINTON, Mass., Oct. 3 /PRNewswire-FirstCall/ -- Caliper Life Sciences, Inc. today announced that the National Institute of Environmental Health Services (NIEHS) has awarded the company a contract valued at up to $7.0 million covering a period of up to ten years at the option of NIEHS. Under the terms of the agreement, Xenogen Biosciences, the in vivo drug discovery services arm of Caliper Discovery Alliances & Services (CDAS), will supply numerous NIEHS investigators with genetically-modified mouse models for research purposes.
The NIEHS focuses its research on the environment and its impact on human health and disease. Working with genetically modified mouse models, including transgenic and gene knockout, enables NIEHS to conduct research aimed at identifying and potentially preventing hazardous conditions and exposure in humans. Beginning immediately, Caliper will develop unique mouse models based on the needs of the research teams at the NIEHS.
The business was awarded to Caliper through a competitive bid process and reflects the company’s expertise and proven ability to design and produce genetic modifications in mice. Caliper has produced more than 9,000 unique mouse and rat models, some of which were previously supplied to the NIEHS under the terms of a previous multi-year agreement.
“This contract is the second significant win for our services business in recent months, following the in vitro Environmental Protection Agency contract announced earlier in the second quarter,” said Kevin Hrusovsky, CEO of Caliper Life Sciences. “Our contract with the NIEHS builds on our existing relationship with this organization and further validates the capabilities of our services organization and the increasing industry demand that is fueling our growth.”
Caliper Discovery Alliances & Services (CDAS) is the services organization created from the integration of NovaScreen Biosciences, a provider of in vitro discovery services, and Xenogen Biosciences, a provider of in vivo discovery services. NovaScreen was acquired by Caliper in October 2005 and Xenogen was acquired by Caliper in August 2006. CDAS provides a wide range of in vitro and in vivo products and services that enable biotechnology and pharmaceutical companies to reduce costs while accelerating the pace and clinical relevance of drug research.
About Caliper Life Sciences
Caliper Life Sciences is a leading provider of cutting-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results and then translating those results into cures for human disease. Caliper’s portfolio of offerings includes state-of-the-art microfluidics, lab automation & liquid handling, optical imaging technologies, and discovery & development outsourcing solutions. For more information please visit http://www.caliperLS.com .
Caliper and Xenogen are registered trademarks of Caliper Life Sciences, Inc.
CONTACT: Schwartz Communications for Caliper Life Sciences, Inc.,
+1-781-684-0770, caliper@schwartz-pr.com
Web site: http://www.caliperls.com/
